FBIOFortress Biotech, Inc.

Nasdaq fortressbiotech.com


$ 2.04 $ -0.01 (-0.49 %)    

Friday, 30-Aug-2024 13:54:16 EDT
QQQ $ 472.58 $ -2.79 (-0.59 %)
DIA $ 413.55 $ -1.30 (-0.31 %)
SPY $ 559.22 $ -1.55 (-0.28 %)
TLT $ 96.85 $ -0.82 (-0.84 %)
GLD $ 231.28 $ -1.11 (-0.48 %)
$ 2.05
$ 2.05
$ 2.03 x 100
-- x --
$ 2.01 - $ 2.07
$ 1.24 - $ 6.26
79,492
na
53.79M
$ 2.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-15-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fortress-biotech-q2-eps-073-beats-123-estimate-sales-1490m-beat-1477m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1....

 hc-wainwright--co-reiterates-buy-on-fortress-biotech-maintains-24-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $24 pric...

 fortress-biotechs-urica-therapeutics-entered-into-an-apa-royalty-agreement-urica-sold-the-rights-to-its-urat1-inhibitor-product-candidate-in-development-for-the-treatment-of-gout-dotinurad-and-related-intellectual-property-licenses-and-agreements-to-crystalys-therapeutics-in-return-for-common-stock-equal-to-35-of-crystalys-outstanding-equity

- SEC Filing

Core News & Articles

Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the a...

 fortress-biotech-announces-pause-in-payment-of-dividends-on-9375-series-a-cumulative-redeemable-perpetual-preferred-stock-pausing-of-these-dividends-will-defer-700k-in-cash-dividend-payments-each-month

Fortress Biotech, Inc. (NASDAQ:FBIO, FBIOP)))) ("Fortress"), an innovative biopharmaceutical company focused on acquiri...

 cantor-fitzgerald-reiterates-overweight-on-fortress-biotech

Cantor Fitzgerald analyst Jennifer Kim reiterates Fortress Biotech (NASDAQ:FBIO) with a Overweight.

 why-is-penny-stock-mustang-bio-trading-over-190-on-monday

Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive resu...

 roth-mkm-reiterates-buy-on-fortress-biotech-maintains-10-price-target

Roth MKM analyst Jason Wittes reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $10 price target.

 fortress-biotech-q1-2024-gaap-eps-103-beats-173-estimate-sales-13030m-miss-14131m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1....

 fortress-biotech-doses-first-paitent-in-multi-center-phase-2-study-of-triplex-for-control-of-cytomegalovirus-in-patients-undergoing-liver-transplantation

Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalo...

 fortress-biotech-q4-eps-053-beats-197-estimate-sales-1995m-beat-1489m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1....

 alliance-global-partners-initiates-coverage-on-fortress-biotech-with-buy-rating-announces-price-target-of-5

Alliance Global Partners initiates coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy rating and announces Price Target of...

 roth-mkm-reinstates-buy-on-fortress-biotech-announces-10-price-target

Roth MKM analyst Jason Wittes reinstates Fortress Biotech (NASDAQ:FBIO) with a Buy and announces $10 price target.

Core News & Articles

Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced com...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION